86 results
424B3
KZIA
Kazia Therapeutics Limited
1 May 24
Prospectus supplement
4:06pm
, minimizing hypoxia and therefore decreases the potential for metastatic spread. The Phase 1 EVT801 monotherapy dose-finding trial targets patients
6-K
EX-99.1
KZIA
Kazia Therapeutics Limited
1 May 24
Kazia Reports Successful Stage 1 Completion of the EVT801
4:01pm
and therefore decreases the potential for metastatic spread. The Phase 1 EVT801 monotherapy dose-finding trial targets patients with histologically
424B3
KZIA
Kazia Therapeutics Limited
27 Mar 24
Prospectus supplement
8:37am
Oligonucleotide) development for undruggable targets in CNS disease including technology for target discovery (SovarIN™), ASO drug discovery & optimization
6-K
EX-99.1
KZIA
Kazia Therapeutics Limited
26 Mar 24
Current report (foreign)
8:02am
for undruggable targets in CNS disease including technology for target discovery (SovarIN™), ASO drug discovery & optimization (SovarON™), and target validation
6-K
EX-99.1
txepuuq7cg
5 Sep 23
Current report (foreign)
7:02am
6-K
EX-99.1
i0avi5dj1 hbr4g7x
26 Jun 23
Kazia Corporate Update and Corporate Presentation
7:00am
6-K
EX-99.1
4tlctbvv
1 Dec 22
Current report (foreign)
4:13pm
6-K
EX-99.1
t6jl27e
15 Sep 22
Current report (foreign)
9:12am
6-K
EX-99.1
e0berypgpcvi1jhf
1 Sep 22
Current report (foreign)
4:07pm
6-K
246tdam
5 Nov 21
Current report (foreign)
6:17am
6-K
dqtssda3 5418a0tk0
19 Apr 21
Current report (foreign)
6:17am
424B5
l1ez3fp3x 0qa00d
31 Mar 21
Prospectus supplement for primary offering
6:30am
6-K
ya8g0yar5uj37492sy4
1 Mar 21
Current report (foreign)
6:06am
6-K
h0j75ke
21 Jun 18
Current report (foreign)
6:16am